Sialic Acid Binding Ig-like Lectin 3
"Sialic Acid Binding Ig-like Lectin 3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 67-kDa sialic acid binding lectin that is specific for MYELOID CELLS and MONOCYTE-MACROPHAGE PRECURSOR CELLS. This protein is the smallest siglec subtype and contains a single immunoglobulin C2-set domain. It may play a role in intracellular signaling via its interaction with SHP-1 PROTEIN-TYROSINE PHOSPHATASE and SHP-2 PROTEIN-TYROSINE PHOSPHATASE.
| Descriptor ID |
D063268
|
| MeSH Number(s) |
D12.776.503.921.400 D23.050.301.264.900.565 D23.101.100.900.565
|
| Concept/Terms |
Sialic Acid Binding Ig-like Lectin 3- Sialic Acid Binding Ig-like Lectin 3
- Sialic Acid Binding Ig like Lectin 3
- CD33 Antigens
- Siglec-3
- CD33 Antigen
- Antigen, CD33
- Glycoprotein gp67
- gp67, Glycoprotein
- Antigens, CD33
|
Below are MeSH descriptors whose meaning is more general than "Sialic Acid Binding Ig-like Lectin 3".
Below are MeSH descriptors whose meaning is more specific than "Sialic Acid Binding Ig-like Lectin 3".
This graph shows the total number of publications written about "Sialic Acid Binding Ig-like Lectin 3" by people in this website by year, and whether "Sialic Acid Binding Ig-like Lectin 3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2002 | 0 | 5 | 5 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 2 | 0 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sialic Acid Binding Ig-like Lectin 3" by people in Profiles.
-
Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile. Blood Adv. 2024 05 14; 8(9):2059-2073.
-
Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study. Leuk Lymphoma. 2024 Sep; 65(9):1281-1291.
-
First-in-human study of JNJ-67571244, a CD33 ? CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome. Clin Transl Sci. 2024 03; 17(3):e13742.
-
Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets. Expert Opin Investig Drugs. 2023 Feb; 32(2):107-125.
-
Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia. 2021 11; 35(11):3282-3286.
-
The CD33 short isoform is a gain-of-function variant that enhances A?1-42 phagocytosis in microglia. Mol Neurodegener. 2021 03 25; 16(1):19.
-
Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. Am J Hematol. 2020 09; 95(9):E225-E228.
-
How I treat acute myeloid leukemia in the era of new drugs. Blood. 2020 01 09; 135(2):85-96.
-
Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy. Br J Haematol. 2019 08; 186(4):538-548.
-
FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia. Clin Cancer Res. 2018 07 15; 24(14):3242-3246.